Momelotinib gets market authorization from the European Commission for patients with MPNs and disease-related splenomegaly or moderate to severe anemia.
Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.
By Joe Hoppe GSK said its Omjjara medicine for the treatment of splenomegaly an enlarged spleen or symptoms in adult myelofibrosis patients with moderate to severe anemia has been authorized.
Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.
The economic calendar for this week has the US Federal.
GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.
The Brentford, West London-based pharmaceutical maker said the European Commission has accepted its application to.